623 results for "krytan tek side effects"

Search for:

Date Range to

623 Results on GlaucomaToday.com

August 2016August 2016

The Literature By Leonard K. Seibold, MD; Malik Y. Kahook, MD; and Jeffrey R. SooHoo, MD

What Is the Real IOP? Laboratory studies may help us better understand our clinical dilemmas.
By Dan Eisenberg, MD

Highlights of the 2016 ARVO Annual Meeting Select research findings presented this year.
By Sze H. Wong, MD, and Albert S. Khouri, MD

News Feature: a New Option for Uveitis Adalimumab, a rheumatology drug, offers hope to patients with this damaging inflammatory eye disease.
By Agustin L. Gonzalez, OD

Glaucoma After Corneal Limbal Stem Cell Transplantation By Ahmad A. Aref, MD; Kavitha R. Sivaramen, MD; and Ali R. Djalilian, MD

Foundations of a Great Physician By Linda Huang, MD

Ocular Surface Disease: Impact on Glaucoma Surgical Decision Making The preoperative planning process is more complex and requires careful attention to the unique issues at play.
By Tony Realini, MD, MPH

The Dark Side of Medication Many systemic and topical drugs can cause or worsen dry eye disease.
By Sarah Marshall, PhD, and Robert Noecker, MD, MBA

Tear Osmolarity in a Glaucoma Practice The role of point-of-care testing in dry eye disease and glaucoma management.
By Leslie E. O’Dell, OD

Corneal Imaging The principles and clinical significance of various technologies.
By Alice T. Epitropoulos, MD

Intense Pulsed Light for Dry Eye Disease This procedure improves the health of the meibomian glands.
By Rolando Toyos, MD

What Every Glaucoma Doctor Should Know About DED New technologies provide more information and better outcomes than ever before.
By Sheri Rowen, MD

Punctal Occlusion and Ocular Nutrition By Paul S. Koch, MD, and Thandeka Myeni, MD, MPH

FDA Approves New Drug for Dry Eye Disease

Neurostimulation: a Novel Approach to Treating the Signs and Symptoms of Dry Eye A device in clinical study could lead to new understanding of dry eye as a neuronal disease.
By John Berdahl, MD

Being a Doctor, Thinking Like a CEO The merging of two mindsets requires skill, versatility, and sensitivity.
By Wolfgang Riha, MD

June 2016June 2016

The Literature By Reena A. Garg, MD, and Helen Jiang, MD

Detecting and Treating Glaucoma in a Myopic Patient Without High IOP By Robert Chang, MD, and Kuldev Singh, MD, MPH

The Eyes of Africa Project Partners bring comprehensive eye care to rural Malawi.
By William Eric Sponsel, MD

Assessing Corneal Biomechanics The importance of these properties rests primarily with their effects on IOP measurement.
By Leon W. Herndon, MD

Evaluating Quality of Life in Glaucoma Understand the impact of the disease to improve care.
By Felipe A. Medeiros, MD, PhD

Do We Need Perimetry? As glaucoma advances, visual field testing provides valuable insight.
By Murray Fingeret, OD

Enhancing Visual Field Testing Techniques to increase the value and reliability of visual fields.
By Oluwatosin Smith, MD

The Role of Optic Nerve Head Imaging Past, present, and future.
By Anitra Turner, MD, and Anjali Bhorade, MD, MSCI

Optical Coherence Tomography as a Glaucoma Screening Tool Does it affect glaucoma detection in the community?
By Lisa F. Rosenberg, MD, and Casey Cahill, MD

Is There Still a Role for Optic Disc Photography? New is not necessarily better.
By George L. Spaeth, MD; Kamran Rahmatnejad, MD; and Lichuan Zeng, BSE

Fighting Side by Side By Sze H. Wong, MD

Down, But Not Out: How the AAO Has Responded to Medicare's 2016 Ophthalmology Fee Cuts Faced with cuts to ophthalmic reimbursements, the American Academy of Ophthalmology sprang into action.
By George A. Williams, MD

Industry News

April 2016April 2016

The Literature By Alex S. Huang, MD, PhD, and Alan T. Begian

What Is the Real IOP? How laboratory glaucoma studies may help us better understand this clinical dilemma.
By Nathan Radcliffe, MD

Screening the Future By Avni Shah, MD

Why I Perform Research in a Clinical Practice Participating in clinical research provides new options for my patients and growth opportunities for my practice.
By Gregory D. Parkhurst, MD

Highlights of the AGS Annual Meeting The latest research findings from the 26th annual meeting of the American Glaucoma Society, held March 3 to 6, 2016, in Fort Lauderdale, Florida.
By Geoffrey T. Emerick, MD

Rho Kinase/Norepinephrine Transporter Inhibition for the Treatment of Glaucoma and Ocular Hypertension An update on the clinical development of a new class of drugs.
By Jason Bacharach, MD

Tools of the Tube Trade By Jonathan S. Myers, MD

February 2016February 2016

The Literature By Andrew Garcia, MD, and Christopher C. Teng, MD

Addressing Poor Adherence By Larissa Habib, MD

Is the Grass Really Greener on the Other Side? The pros and cons of ophthalmology business models.
By Richard A. Lehrer, MD

Dealing With Reimbursement Cuts Two surgeons share their strategies.
By Paul F. Palmberg, MD, PhD, and Jeffrey A. Kammer, MD

12345678910111213141516 | Next >